The study found that a specific strain, Sm6, is widely distributed worldwide and carries key virulence genes and resistance genes. This suggests a possible mechanism for the spread of different S. maltophilia subtypes in hospital settings.
A recent trial of a MERS coronavirus vaccine candidate has shown promising results, with the vaccine inducing antibody and T cell responses in nearly all trial subjects. The findings have implications for the development of a vaccine against SARS-CoV-2, with plans to conduct further trials.
A novel HIV antibody, 1-18, has been identified as a highly potent and effective treatment option. Unlike other antibodies, it prevents the development of viral resistance, maintaining suppressed viral loads for extended periods.
Researchers have discovered a novel peptide, Darobactin, effective against antibiotic-resistant gram-negative bacteria. The substance binds to the BamA protein, disrupting the bacterial external membrane and leading to its death. This finding presents a promising lead for developing a new antibiotic.
Scientists have decoded the immune response to the Ebola vaccine, revealing a broad range of antibodies against the virus. The research, led by Prof. Klein, found that different sites on the envelope protein of the virus were recognized and many antibodies exhibited high neutralising activity.
Researchers identified a new, highly virulent form of Listeria monocytogenes that causes severe diseases in animals and humans. The strain was discovered in China and combines the virulence characteristics of various highly pathogenic Listeria species into a single isolate.
Researchers have identified an unusual hepatitis B virus in shrews, which lacks a key protein essential for chronic infection. This discovery offers new insights into the disease's pathogenesis and may lead to the development of effective treatments.
Researchers discovered a new class of antibiotics produced by the microbiome that kill bacteria by disrupting their energy metabolism. Fibupeptides, such as lugdunin, have shown promise in treating multidrug-resistant infections, including those caused by MRSA.
Researchers from Germany have found that a previous dengue infection can protect against Zika-associated damage. This discovery has important implications for pregnant women, particularly those living in regions with high Zika virus prevalence.
Researchers have identified a new target protein that can inhibit Mycobacterium tuberculosis-induced cell death. Corticosteroids, already used in tuberculosis treatment, may support the healing process by inhibiting this pathway. This immunotherapy approach could reduce treatment duration and secondary complications associated with TB.
Researchers highlight diagnostic pitfalls in Zika and Chikungunya virus detection, particularly for Zika, where false positives can have fatal consequences. Combined testing methods offer higher reliability, with sensitivity improved through the use of Immunoglobulin A (IgA) as a marker.
Scientists at Helmholtz Zentrum München have developed an analytic method that can precisely detect viral infections using immune responses. This method could help identify gaps in protection early on and make transplants safer in the future.
Researchers have discovered a previously unknown protein called TarP that helps multi-resistant bacteria evade the human immune system. This breakthrough could lead to new therapies against MRSA and other resistant pathogens.
A large-scale genome analysis of over 10,000 TB pathogen strains has shown that genome sequencing can improve treatment and potentially replace traditional resistance testing. This method enables precise prediction of drug resistance and individualized treatment plans, saving resources and time.
A novel combination of broadly neutralizing antibodies has shown remarkable results in reducing HIV viral loads in infected individuals, even after treatment interruptions. This groundbreaking study suggests a promising approach to antibody-mediated therapy, paving the way for long-term control of the virus.
A study by German Center for Infection Research scientists found that molecular diagnostic tests for the Zika virus in Brazil were not always reliable, resulting in false-positive or false-negative results. This highlights the need for reliable diagnostics to prevent fatal consequences and inform preventive measures.
Scientists from the German Center for Infection Research found that the Zika virus has a high seroprevalence rate in Salvador, northeastern Brazil, suggesting that further outbreaks are unlikely. The study linked this finding to increased population immunity and socioeconomic factors such as poverty.
Researchers identified a signature of five early innate immune markers correlating with antibody titers after vaccination, providing insight into VSV-based vaccine efficacy. The study's findings could lead to accelerated vaccine development and improved emergency vaccine strategies.
Researchers at German Center for Infection Research develop a new malaria vaccine that uses fully viable malaria parasites, showing up to 100% protection against the disease. The vaccine was tested on 67 healthy adult subjects and showed strong immune responses.
A rapid genotypic resistance test for colistin has been developed to detect the mobile resistance gene mcr-1, which threatens emergency antibiotics. The test demonstrated 100% sensitivity and specificity in detecting mcr-1 on plasmids.
A new substance, SC83288, has been successfully used to treat severe malaria in humanised mice, killing the parasites in a short period of time. The substance was chemically modified from benzamidine derivatives to increase its effectiveness and tolerability without forfeiting its action against parasites.
Researchers have identified a key mechanism behind the aggressive progression of skin infections caused by Community-Associated MRSA strains. The discovery suggests that modifying the bacterial cell envelope could help prevent such infections.
A new HIV antibody, 10-1074, has been successfully tested on humans, demonstrating high antiviral activity and favourable pharmacokinetic properties. The trial also investigated the development of resistant HIV variants, providing valuable insights into the potential treatment approach.
A team of scientists analyzed TB bacterial strains and found they can be genetically subdivided into generalists with worldwide distribution and specialists with localized ecological niches. Generalists have a slightly increased diversity of antigens, allowing them to adapt more specifically to different human populations.
Researchers have found that common cold coronaviruses originate from camels, similar to the MERS virus. The study suggests a potential scenario for MERS emergence and highlights the need for a vaccine against MERS.
According to a German study, nearly 10% of hospital patients carry multidrug-resistant bacteria from home, increasing the risk of transmission. The study highlights the importance of improving hygiene measures, reducing antibiotic use, and increasing training for doctors to prevent the spread of these deadly pathogens.
A recent study conducted in Tanzania found that an infection with the filarial nematode Wuchereria bancrofti increases the risk of HIV infection by two to three fold. The study revealed a significant association between filarial infections and increased risk of HIV infection, particularly among adolescents and young adults.
A prospective, multinational study investigating virological and immunological changes due to HIV prior to clinical symptoms has identified 112 people with newly acquired infections just days after HIV exposure. The study provides valuable insights into the early stages of HIV infection and its impact on immune defense mechanisms.
Researchers have found that antibiotic-resistant salmonella strains are becoming increasingly common in sub-Saharan Africa, posing a significant threat to public health. The emergence of multidrug-resistant strains, particularly among non-typhoid salmonella infections, is a major concern due to the lack of effective treatments.
DZIF scientists have developed optimized assays and a control for quantifying viruses in blood and urine, improving the reliability of current tests. The new tests are more sensitive to low viral concentrations and comparable across different strains.
A phase I trial of the rVSV-ZEBOV vaccine in Africa and Europe has shown promising results, with antibodies detectable after six months. The vaccine stimulates a strong immune response and appears to control virus replication.